| Name | Title | Contact Details |
|---|
Parastar is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shook Home is a Chambersburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Many well-being programs give you tools to manage your health. We go deeper. WellSpark is a leading health and well-being company that administers one of the largest value-based well-being programs in the country. Our well-being portal is certified for information security by the Health Information Trust (HITRUST) Alliance, and our health risk assessment earned the Wellness and Health Promotion certification form the National Committee for Quality Assurance (NCQA). WellSpark delivers a full-suite of well-being products and solutions for businesses, municipalities, and consumers. Participants benefit from robust education to improve health literacy, promote early detection of diseases and provide condition management through coaching, care coordination, social services and more. By understanding any socio-economic and behavioral barriers preventing proper self-care, WellSpark programs can uniquely empower individuals to embrace healthier lifestyles. Lives improve when well-being solutions spark results. Go beyond basic health and well-being with WellSpark Health.
NeoLife is a pioneer in whole food nutrition supplementation since 1958, with a commitment to end the trend of poor wellness and poverty.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.